Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCHE | P06276 | 5/20 | 0.46 |
| ▸ | MAOB | P27338 | 3/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | ATM | Q13315 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | LTA4H | P09960 | 1/20 | 0.40 |
| ▸ | DRD4 | P21917 | 2/20 | 0.40 |
| ▸ | TMEM97 | Q5BJF2 | 2/20 | 0.40 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.40 |
| ▸ | ACHE | P22303 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2234962 | 0.94 | LTA4H (0.42) | BCHEKDM4ELTA4H | |
| SCHEMBL2237424 | 0.89 | S1PR5 (0.40) | BCHEMAOBKDM4ELTA4H | |
| SCHEMBL2240254 | 0.87 | KDM4E (0.45) | BCHEKDM4ELTA4HSIGMAR1 | |
| SCHEMBL2237326 | 0.86 | ALDH1A1 (0.54) | ATML3MBTL1ALDH1A1LTA4H | |
| SCHEMBL2236465 | 0.81 | ALDH1A1 (0.44) | ALDH1A1LTA4H | |
| SCHEMBL2238588 | 0.79 | ALDH1A1 (0.44) | KDM4EALDH1A1KMT2A | |
| SCHEMBL2239983 | 0.79 | HDAC1 (0.47) | KDM4ELTA4H | |
| SCHEMBL1935382 | 0.79 | S1PR1 (0.42) | ALDH1A1 | |
| SCHEMBL2237876 | 0.79 | FUCA1 (0.42) | KDM4EALDH1A1 | |
| SCHEMBL2239911 | 0.78 | LTA4H (0.49) | LTA4HDRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110201589-A1 | NEW BRADYKININ B1 ANTAGONISTS | EVOTEC AG (DE) | 2011-08-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110201589-A1 | NEW BRADYKININ B1 ANTAGONISTS | BDKRB1, BDKRB2, BRS3 | BCHE 765/4885MAOB 218/4885KDM4E 2968/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.